Drug
Liposomal Amikacin For Inhalation
Liposomal Amikacin For Inhalation: highest development phase Phase 3, developed by Insmed. 4 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Insmed
Trials
| Drug | Phase | Indication |
|---|---|---|
| Liposomal amikacin for inhalation NCT01316276 | Phase 3 | Cystic Fibrosis |
| Liposomal amikacin for inhalation NCT01315691 | Phase 3 | Cystic Fibrosis |
| Liposomal amikacin for inhalation (LAI) NCT01315236 | Phase 2 | Mycobacterium Infections, Nontuberculous |
| Liposomal Amikacin for Inhalation NCT05999942 | Phase 1 | Healthy Volunteers |
Latest
No recent events.
Follow Liposomal Amikacin For Inhalation on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.